Search
Clinician Ordering Portal
Scientific evidence
Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma
Jan 2022
Over 50% of newly diagnosed cutaneous squamous cell carcinoma (cSCC) lesions occur in the head and neck (cSCC‐HN), and metastasis to nodal basins in this region further complicates surgical and adjuvant treatment.
Publication: Laryngoscope Investig Otolaryngol.
Molecular research in uveal melanoma: ushering in a new standard of care
Jan 2022
Publication: Retina Times
Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test
Nov 2021
To clinically validate the 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma patients and evaluate coupling the test with individual clinicopathologic risk factor-based assessment methods.
Publication: Future Oncology
Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31-gene expression profile test
Oct 2021
Patient survery performed in conjunction with Melanoma Research Foundation on patient attitudes towards prognostic testing
Publication: Cancer Medicine
The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma
Sep 2021
DecisionDx-Melanoma significantly stratified patient risk for RFS, DMFS, and MSS (p < 0.001) and was a significant, independent predictor of metastatic recurrence (hazard ratio: 5.38; p = 0.014).
Publication: Future Oncology
Integrating 31-Gene expression profiling with clinicopathologic features to optimize cutaneous melanoma sentinel lymph node metastasis prediction
Sep 2021
Validation of integrated 31-GEP (i31-GEP) neural network algorithm incorporating clinicopathologic factors with the continuous 31-GEP score for personalized SLNB positivity risk assessment.
Publication: JCO Precision Oncology
Clinical considerations for integrating gene expression profiling into cutaneous squamous cell carcinoma management
Jun 2021
Gene expression profile (GEP) testing is now commercially available for metastatic risk prediction in patients with cutaneous squamous cell carcinoma (CSCC) and one or more high-risk factors.
Publication: JDD
Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management
May 2021
To integrate gene expression profiling into the management of high-risk cutaneous squamous cell carcinoma (cSCC) within the National Comprehensive Cancer Network (NCCN) guidelines to improve risk-aligned management recommendations.
Publication: Curr Med Res Opin
Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma
May 2021
To determine how results from a prognostic 40-gene expression profiling (40-GEP) test would impact clinician management decisions and how their choices would align with a National Comprehensive Cancer Network (NCCN) compliant, risk-directed management plan for high-risk cutaneous squamous cell carcinoma (cSCC).
Publication: Curr Med Res Opin
Clinical use of a diagnostic gene expression signature for melanocytic neoplasms
May 2021
Patients managed in accordance with a benign 23-GEP result, including forgoing re-excision, reported no adverse events during the follow-up period.
Publication: Cutis
Tissue systems pathology test objectively risk stratifies Barrett’s esophagus patients with low-grade dysplasia
Apr 2021
The risk prediction assay provided significant risk stratification in BE patients with LGD and identified progressors that the experts downstaged to NDBE.
Publication: American Journal of Gastroenterology
Long-term outcomes in a multicenter, prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma
Apr 2021
Prospective analysis reporting long-term outcomes for patients tested with DecisionDx-Melanoma (follow-up to study first published as Hsueh, 2017).
Publication: JCO Precision Oncology